Edition:
United Kingdom

People: Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

0.35USD
16 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.35
Open
$0.32
Day's High
$0.38
Day's Low
$0.31
Volume
145,801
Avg. Vol
36,355
52-wk High
$1.59
52-wk Low
$0.25

Mazzo, David 

Dr. David J. Mazzo, Ph.D. is appointed as Director of the Company, effective June 12, 2019. Dr. Mazzo brings over 30 years of experience in the pharmaceutical industry, and currently serves as Chief Executive Officer of Caladrius Biosciences, a clinical-stage biopharmaceutical company committed to the development of innovative products in cardiovascular and autoimmune diseases. Dr. Mazzo has also served as: Chief Executive Officer and as a member of the board of directors of Regado Biosciences, Inc., a NASDAQ-listed biopharmaceutical company; President, Chief Executive Officer and a director of Æterna Zentaris, Inc. (NASDAQ: AEZS) and President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. In addition, Dr. Mazzo has also held senior management and executive positions in a number of public and private pharmaceutical and biotech companies. Dr. Mazzo earned a BA in the Honors Program (interdisciplinary humanities) and a BS in chemistry from Villanova University. In addition, Dr. Mazzo received his MS in chemistry and his PhD degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --